Healthtech Leader Eon Announces 1MM Patients Impacted by Their Incidental Findings and Screening Software

Eon, a leading provider of incidental findings and screening patient management software, announced today that it has surpassed 1MM patients impacted by their proprietary AI software and services.

Eon provides a cloud-based patient management platform that enables hospitals and health systems to capture and longitudinally track patients at risk for future catastrophic diagnoses, creating a stage shift in the early detection of cancer and possible prevention of ruptured aneurysms.

Dr. Aki Al-Zubaidi, Eon Founder & CEO, is an Interventional Pulmonologist who founded Eon in 2013 to solve a clinical problem he experienced firsthand – lung cancer was most often diagnosed at a late stage where the likelihood of survival for those diagnosed was low. He knew that by tracking patients with lung nodules found early on regular radiology exams, he could diagnose lung cancer at earlier stages. He also knew the solution Eon had created was scalable and has since been deployed for multiple diseases including Pancreas, Liver, Thyroid, AAA, and Breast, with a considerable number of disease solutions in development. Eon continues to lead with patient care at the forefront of its mission while providing solutions that create significant service line growth and impactful downstream revenue for its customers.

“I am incredibly proud that we have achieved a significant milestone by positively impacting over 1,000,000 individuals,” said Dr. Al-Zubaidi. “This accomplishment is a testament to the dedication, tireless efforts, and collective action of our entire team, as well as our unwavering commitment to making patients healthy and healthcare affordable. We remain committed to the pursuit of further advancements as we continue to push boundaries, invest in innovative solutions, and strive for excellence in delivering life-saving solutions that make financial sense. Our ultimate goal is to touch the lives of millions more, creating a lasting impact on global healthcare outcomes.”

The Eon Patient Management (EPM) platform leverages computational linguistics, an advanced form of artificial intelligence, along with robust data science models to accurately capture incidental findings in healthcare records. EPM triages patients that need a follow-up exam, automates communication with patients and providers, and flags the care team when exams are ordered, completed, missed, or overdue. Eon also offers a tech-enabled care navigation service that helps hospital care teams offload administrative tasks and reach more patients. “Because of the early intervention that many of these people have received, their opportunity to live a full, healthy life has been positively impacted. These million patients represent our neighbors, brothers, sisters, parents and friends,” said Dr. Scott Skibo, Chief Medical Officer at Eon Health.

Today, Eon is used by over 45 health systems and 500+ facilities across the United States. Notable partner health systems include UCHealth, LifePoint Health, HCA Healthcare, Ascension, Hospital Sisters Health System, Cleveland Clinic, and Geisenger.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”